COST-EFFECTIVENESS ANALYSIS OF DAPTOMYCIN VERSUS VANCOMYCIN IN COMPLICATED SKIN AND SOFT STRUCTURE INFECTION (CSSSI) USING A DECISION ANALYTIC MODEL

被引：0
|
作者：
Zargarzadeh, A. [1 ]
Bounthavong, M. [2 ]
Hsu, D. [1 ]
Okamoto, M. P. [3 ]
机构：
[1] Western Univ Hlth Sci, Coll Pharm, Pomona, CA USA
[2] VASDHS, San Diego, CA USA
[3] Univ Hawaii, Coll Pharm, Hilo, HI 96720 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73620-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A111 / A112
页数：2
相关论文
共 50 条
  • [1] Decision analytic model evaluating the cost-effectiveness of linezolid versus vancomycin in methicillin-resistant staphylococcus aureus complicated skin and soft tissue infection
    Bounthavong, M.
    Okamoto, M. P.
    Hsu, D.
    VALUE IN HEALTH, 2008, 11 (03) : A97 - A97
  • [2] Cost-Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections
    Laohavaleeson, Somvadee
    Barriere, Steven L.
    Nicolau, David P.
    Kuti, Joseph L.
    PHARMACOTHERAPY, 2008, 28 (12): : 1471 - 1482
  • [3] Cost-Effectiveness Analysis of Linezolid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus: Complicated Skin and Skin Structure Infection Using Bayesian Methods for Evidence Synthesis
    Bounthavong, Mark
    Zargarzadeh, Amir
    Hsu, Donald I.
    Vanness, David J.
    VALUE IN HEALTH, 2011, 14 (05) : 631 - 639
  • [4] Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model
    Bounthavong, M.
    Hsu, D. I.
    Okamoto, M. P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 376 - 386
  • [5] A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH FAILURE TO VANCOMYCIN THERAPY IN MEXICO
    Briones, B.
    Revelles, Martinez M.
    Garcia-Contreras, F.
    VALUE IN HEALTH, 2011, 14 (03) : A118 - A119
  • [6] Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany
    Schuermann, Dirk
    Sorensen, Sonja V.
    De Cock, Erwin
    Duttagupta, Sandeep
    Resch, Ansgar
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2009, 10 (01): : 65 - 79
  • [7] Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany
    Dirk Schürmann
    Sonja V. Sorensen
    Erwin De Cock
    Sandeep Duttagupta
    Ansgar Resch
    The European Journal of Health Economics, 2009, 10
  • [8] Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue Infections in France
    De Cock, E.
    Sorensen, S.
    Levrat, F.
    Besnier, J. -M.
    Dupon, M.
    Guery, B.
    Duttagupta, S.
    MEDECINE ET MALADIES INFECTIEUSES, 2009, 39 (05): : 330 - 340
  • [9] Daptomycin versus vancomycin for complicated skin and skin structure infections: Clinical and economic outcomes
    Davis, Susan L.
    McKinnon, Peggy S.
    Hall, Levi M.
    Delgado, George, Jr.
    Rose, Warren
    Wilson, Robert E.
    Rybak, MichaelJ.
    PHARMACOTHERAPY, 2007, 27 (12): : 1611 - 1618
  • [10] Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
    Nathwani, Dilip
    Cornely, Oliver A.
    Van Engen, Anke K.
    Odufowora-Sita, Olatunji
    Retsa, Peny
    Odeyemi, Isaac A. O.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) : 2901 - 2912
12345